A DOUBLE-BLIND, PLACEBO-CONTROLLED EVALUATION OF THE ANXIOLYTIC EFFICACY FF AN ETHANOLIC EXTRACT OF WITHANIA SOMNIFERA by Andrade, Chittaranjan et al.
Indian Journal of Psychiatry, 2000, 42 (3), 295-301 
A DOUBLE-BLIND, PLACEBO-CONTROLLED EVALUATION 
OF THE ANXIOLYTIC EFFICACY OF AN ETHANOLIC 
EXTRACT OF WITHANIA SOMNIFERA 
CHITTARANJAN ANDRADE, ANITHA ASWATH, S.K. CHATURVEDI, 
M. SRINIVASA & R. RAGURAM 
ABSTRACT 
A double-blind, placebo-controlled study was conducted to evaluate the efficacy an ethanolic 
extract of Aswagandha (Withania somnifera), in patients with ICD-10 anxiety disorders. The sample 
comprised 39 subjects, of whom 20 received the drug and 19 received placebo. The two groups 
were sociodemographically and clinically similar at baseline. At 2 and 6 weeks follow-up, data from 
approximately 85% of patients in each group were available for analysis. Statistical trends favouring 
the drug were observed at both time points. At 6 weeks, significantly more patients met a priori 
response criteria in the drug group (88.2%) as compared with the placebo group (50%). The drug 
was well-tolerated and did not occasion more adverse effects than did placebo. It is concluded that 
this ethanolic extract of Withania somnifera has useful anxiolytic potential and merits further 
investigation. 
Key words: Anxiety disorder, generalized anxiety disorder, adjustment disorder with anxiety, 
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Anxiety disorders are common, and have 
a lifetime prevalence that exceeds 15% in the 
general population (Kessler et al., 1994). 
Conventional anxiolytic treatments include the 
benzodiazepines, antidepressant drugs in low 
doses, and buspirone. All these three categories 
of drugs are associated with disadvantages in 
the management of anxiety. Benzodiazepines 
and antidepressant drugs occasion sedation and 
impaired psychomotor performance; while 
benzodiazepine therapy results in drug 
dependence, antidepressant therapy is 
associated with anticholinergic and/or other 
adverse effects. Antidepressant drugs and 
buspirone may both produce initial worsening of 
anxiety (Andrade,2000). There is therefore a 
need for the development of anxiolytic therapies 
that carry fewer disadvantages to the patient. 
In India, Aswagandha (Withania 
somnifera) has been used for centuries in 
Ayurvedic medical practice to reduce symptoms 
of anxiety and stress (Iyengar, 1981; Handa,1995; 
Satyavati,1995). In laboratories in the USA, 
Withania somnifera extracts have been shown 
to possess high affinity for GABA receptors (Cott 
et al.,1994). The experimental drug is an 
ethanolic extract of Withania somnifera. In Indian 
research, this extract has been shown to have 
GABA-mimetic properties (Mehta et al .1991; 
Kulkarni et al.,1993), which might conceivably 
mediate its demonstrated anticonvulsant 
(Kulkarni et al.,1993; Kulkarni & George,1996) 
and antikindling (Kulkarni et al., 1994) actions. 
Since GABA agonism has b< en linked to 
anxiolysis (Stahl,1998), these findings support 
the recommendation in A"urveda that 
Aswagandha be used for tranquillization. 
Extracts of Aswagandha may therefore be useful 
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in anxiety disorders that present in psychiatric 
practice. 
In an unpublished open clinical trial (data 
on file; available upon request from 
manufacturer), Dave at the Rasiklal Shah 
Sarvajanik Hospital, Gujarat, studied the efficacy 
and safety of ethnolic extract of Aswagandha 
250 mg twice daily in 50 patients with anxiety 
disorders. By the end of the first month of 
treatment, 36 (72%) of patients showed 
moderate to excellent improvement, in about half 
of these cases, benefits were observed within 
the first fortnight. These 36 patients were 
continued on the drug for a maximum of 18 
months, during which period the medication was 
withdrawn under psychotherapeutic support. It 
was observed that the drug satisfactorily 
attenuated anxiety symptoms and did not 
occasion any adverse effects of note. 
In view of the encouraging laboratory and 
clinical results, a double-blind, placebo-
controlled, dose-ranging study was designed to 
assess the anxiolytic efficacy and adverse effects 
of this ethanolic extract of Aswagandha. 
MATERIAL AND METHOD 
The sample comprised consecutive 
patients diagnosed with ICD-10 generalized 
anxiety disorder, mixed anxiety and depression, 
panic disorder, and adjustment disorder with 
anxiety. The sample was recruited from two 
clinical units in a large mental hospital setup, 
and from a private psychiatric hospital, both 
located in urban India. The study was conducted 
on an outpatient basis. 
Patients were recruited only if their treating 
consultant considered them to be sufficiently 
symptomatic to warrant further pharmaco-
therapeutic intervention Further selection criteria 
included an absence of significant past or current 
history of cigarette smoking, drug or alcohol 
abuse, or medical or psychiatric illness that may 
have prejudiced the diagnosis or ratings of 
anxiety, or the response to anxiolytic medication. 
Informed consent was obtained in writing from 
recruited patients. The project protocol received 
the approval of the Ethics Committee in the 
institution of the first author. 
Patients were randomized to receive 
either ethnolic extract of Aswagandha (250 mg/ 
tablet) or placebo, administered as identical 
tablets in the dose of 2 tablets twice a day. The 
first follow-up was conducted after 2 weeks, at 
which time a decision was taken to lower or raise 
the dose based upon the clinical response and 
the adverse effects reported. Subsequently, dose 
titrations to individual requirements were allowed 
at weekly intervals, subject to a minimum of 2 
and a maximum of 10 tablets per day. For ethical 
reasons, existing medications (if any) were 
continued unchanged throughout the course of 
the study. No other medication, or any other form 
of therapeutic intervention, was prescribed 
during the study. 
Patients were assessed at baseline, at 
week 2, and at week 6 (the treatment endpoint) 
using the following instruments : 
1. Hamilton Anxiety Scale (Bech et at., 1986); 
assessed by the rater only. 
2. Global Rating Scale; assessed separately by 
patient and rater. This instrument had rating 
points anchored as follows : 0=no symptoms; 
1=mild symptoms; 2=moderate symptoms; 
3=severe symptoms; 4=very severe symptoms. 
Decimal ratings were encouraged. 
3. Systematic assessment for treatment 
emergent effects (SAFTEE) symptom checklist 
(Levine & Schooler, 1986), assessed by the rater 
only, and at weeks 2 and 6 only. 
Patients and raters were alike blind to the 
treatment allocation until after the study 
endpoint. 
Statistical analysis : Baseline data were analyzed 
for all recruited patients. Efficacy and adverse 
effects data were analyzed only for those patients 
who provided follow-up assessments at week 2 
and beyond. The last observation carried forward 
(LOCF) method was employed for all patients 
who completed the first-fortnight assessment but 
who dropped out subsequently. Response was 
defrned a priori as a reduction in Hamilton 
296 ANXIOLYTIC EFFICACY OF ETHANOLIC EXTRACT OF WITHANIA SOMNIFERA 
Anxiety score to 12 or below, associated with a 
global rating from both patient and rater of not 
more than 1 (mild symptoms). 
Proportions were compared between 
groups using the X
2 test (with Yates continuity 
correction for 2x2 contigency tables), or the 
Fisher's exact 2-tail probability test when the 
requirements for X
2 testing were not met. Means 
were compared between groups using the 
independent sample student's 't' test, with 
modified degrees of freedom wherever indicated 
to correct for heterogeneity of variances as 
determined by the Fmax test. When distributions 
were non-normaJ, mean ranks between groups 
were compared using the Mann-Whitney U test 
with z corrected for ties. Means were compared 
between groups and across time using repeated 
measures multivariate analysis of variance 
(RMANOVA); Pillai's trace was selected as the 
test criterion. 
RESULTS 
The sample comprised 39 subjects, of 
whom 20 received the experimental drug and 
19 received placebo. The sample was 61.5% 
male, and the mean (standard deviation) [M 
(SD)] age of the sample was 41.3 (13.8) years. 
The sociodemographic and clinical variables of 
the sample are presented in tables 1-3. There 
were no significant differences between 
experimental drug and placebo groups at baseline. 
At the end of week 2, when the first follow-
up assessments were due, 3 patients belonging 
to each group dropped out of the study, and 
attempts to trace them to ascertain the reasons 
for drop put failed. These 6 patients could not 
TABLE 1 
AGE AND SEX DISTRIBUTION IN DRUG 
(N=20) AND PLACEBO (N=19) GROUPS* 
Variable 
Age (in yrs.) 
Range 
(MeanS.D.) 
Sex: Male 13 
Female 
Drug group 
18-68 
41.9(14.4) 
t=0.27,d.f.= 
11 
7 
Placebo 
18-69 
40.7(13.4) 
37, NS 
8 
X
,=0.02, d.f.=1, NS (with yates correction) 
TABLE 2 
DIAGNOSTIC BREAKUP OF DRUG (N-20) 
AND PLACEBO (N=19) GROUPS 
Diagnosis 
Generalized 
anxiety disorder 
Mixed anxiety 
and depresssion 
Adjustment 
disorder with 
anxiety 
Panic disorder 
Drug group 
13 
3 
2 
2 
Placebo 
11 
5 
1 
2 
TABLE 3 
BASELINE CLINICAL DESCRIPTION OF DRUG 
(N=20) AND PLACEBO (N=19) GROUPS* 
Variable 
Duration of 
Drug group 
0.5-40 
illness (years) 7.4(10.3) 
Hamilton 
Anxiety score 
Global 
rating 
(patient) 
Global 
rating 
(rater) 
15-28 
17.3(6.4) 
1-4 
2.6 (0.8) 
1-4 
2.5(0.9) 
Placebo 
0.2-20 
6.4(6 3) 
15-28 
18.6(4.5) 
2-4 
2.8(0.5) 
1-4 
2.8 (D.6) 
Significance* 
z=0.21,NS 
t?0.72. d.f.=37 
NS 
t=1.10, 
d.f.=31.6,NS 
t=0.98, 
d f.=37, NS 
* data presented are range, mean and standard deviation. 
# Mann-Whitney U test with z corrected for ties, and 
independent sample Student's t' test with modified d.f.. whereve 
indicated. to correct for heterogeneity of variances. 
be assessed on any measure at week 2. At week 
6, a further 6 experimental drug patients and 7 
placebo patients withdrew from the study. 
Reasons for withdrawal are presented in table 
4. There were no significant differences between 
groups in individual reasons for withdrawal. 
At baseline, according to the protocol, all 
TABLE 4 
REASONS FOR DROUP OUT IN DRUG (N-20) 
AND PLACEBO (N=19) GROUPS 
Reason for Drug group Placebo 
droup out 
Lack of benefit 3 3 
Adverse effects 2 3 
Other" 1 1 
Unknown" 3 3 
* These patients developed a crisis in their personal 
environments, which necessitated more intensive 
medication. 
" These patients dropped out before the first follow-up; all 
other patients completed at feast one follow-up. 
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patients were advised to take two tablets twice 
daily. At week 2, based on initial response, 
patients were advised 2-6 tablets/day with a 
M(SD) of 4.5 (1.1) tablets in the drug group, and 
2-6 tablets/day with a M(SD) of 4.3 (1.5) tablets 
in the placebo group. The difference between 
groups was not significant (t=0.57, d.f.=31, NS). 
At week 6, the patients were receiving 2-9 
tablets/day with a M(SD) of 5.0 (2.1) tablets in 
the drug group, and 2-8 tablets/day with a M(SD) 
of 4.7 (2.0) tablets in the placebo group. The 
difference between groups was again not 
significant (t=0.40, d.f.=21, NS). 
Efficacy and adverse effect data were 
available for 17 of the 20 experimental drug 
patients (85%) and for 16 of the 19 placebo 
patients (84.2%). At the second week, 12 of 17 
experimental drug patients (70.6%) met criteria 
for response, while 6 of 16 placebo patients 
(37.5%) were similarly classified; the difference 
was however not statistically significant (X
2=2.43, 
d.f.=1, NS). At the sixth week, 15 of 17 drug 
patients (88.2%) met criteria for response, while 
8 of 16 placebo patients (50%) were similarly 
classified; the difference was statistically 
TABLE 5 
RANGE, M(SD) CHANGE IN HAMILTON ANXIETY 
SCORES ACROSS TIME IN DRUG (N=17) 
AND PLACEBO (N=16) GROUPS" 
Drug 
Placebo 
Week 2 
5-22 
11.0(4.7) 
4-25 
14.1(5 6) 
Week 6 
0-22 
8.5(5.3) 
4-25 
12.2(5.6) 
* baseline data have been presented In Table 3. 
# statistical trends favoured the drug group at both week 
2 and week 6. 
significant (Fisher's exact two-tailed 
probability=0.026). 
A quantitative examination of anxiety 
scores across time (Table 5) showed that both 
groups improved significantly (Pillai's trace=0.68, 
F=32.13, d.f.=2,30, p<0.001) from week 2 itself. 
There was a main effect for drug that approached 
significance (F=3.35, d.f. = 1,31, p=0.077). 
Independent comparisons at week 2 (t=1.70, 
d.f.=31, p=0.098) and week 6 (t=1.94, d.f.=31, 
p=0.062) revealed statistical trends that favoured 
the experimental drug. 
A quantitative examination of changes in 
global scores across time (Table 6) showed 
significant improvements for both patient (Pillai's 
trace=0.73, F=40.56, d.f.=2,30, p<0.001) and 
rater-assessed (Pillai's trace=0.66, F=29.60, 
d.f.=2,30, p<0.001) functioning from week 2 
itself. No significant advantage for experimental 
drug was however obtained in either the former 
(Pillai's trace=0.02, F=0.25, d.f.=2,30, NS)orthe 
latter (Pillai's trace=0.02, F=0.31, d.f.=2,30, NS) 
assessments. Independent testing at each of 
weeks 2 and 6 again did not demonstrate an 
advantage for experimental drug. 
A quantitative analysis of adverse effects 
(Table 7) showed that 15 experimental drug 
treated patients reported a M(SD) of 1.2 (1.2) 
adverse effects at week 2, and 8 patients 
reported a M(SD) of 0.25 (0.5) adverse effects 
at week 6. Corresponding data for placebo-
treated patients were 0.9 (1.1) from 15 patients 
at week 2, and 0.67 (1.1) from 9 patients at week 
6. The difference between groups was not 
significant either at week 2 (Mann-Whitney; 
z=0.80, NS) or at week 6 (Mann-Whitney, 
TABLE 6 
RANGE, M(SD) GLOBAL ASSESSMENTS OBTAINED FROM PATIENTS AND RATER AT 
WEEK 2 AND 6 IN DRUG (N«17) AND PLACEBO (N*16) GROUPS ## 
Drug 
Placebo 
Patients' assessment 
Week 2 
0.5-3 
1.9 (0.8) 
0.5-3.5 
2.2 (1.0) 
Week 6 
0-3 
1.4 (0.9) 
0-3.5 
1.8 (1.0) 
Rater's assessment 
Week 2 
0.5-3 
1.8 (0.7) 
0.5-3 
2.0 (0.9) 
Week 6 
0-3 
1.4 (0.9) 
0.5-3 
1.8 (0.8) 
* baseline data have been presented in Table 3. 
# there were no differences between drug and placebo groups at either week 2 or week 6. 
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TABLE 7 
FREQUENCY OF EXPERIENCE OF ADVERSE 
EFFECTS AT WEEKS 2 AND 6 
Number of advers effects reported 
none 1 2 3 
At week 2 
Drug group 6 3 3 3 
Placebo group 6 2 4 1 
At week 6 
Drug group 6 2 0 0 
Placebo group 6 111 
Z=0.60, NS). 
A qualitative analysis of adverse effects 
is presented in table 8. With the possible 
exception of greater drowsiness, heaviness of 
head and related symptoms with Aswagandha 
(during the initial few days only), there were no 
differences between groups in the nature and 
frequency of individual adverse effects. The 
treatments were in general well-tolerated, with 
TABLE 8 
ADVERSE EFFECTS REPORTED BY DRUG (N*17) 
AND PLACEBO (N»16) PLANTS 
Adevrse effect 
Giddiness 
Drowsiness 
Dullness 
Heaviness of head 
Increased frequency 
of migraine 
Fatigue 
Withdrawal fatigue 
Chest pain 
Chest infection 
Itching 
Burning eyes 
Burning urine 
Numb hands 
Multiple somatic 
complaints 
Heat in body 
Bitter taste 
Decreased appetite 
Increased appetite 
Decreased sleep 
Gastritis 
Heaviness in stomach 
Diarrhoea 
Menstrual irregularities 
Worsening of obsessive-
compulsive disorder 
Drug group 
0 
2 
0 
4 
1 
1 
1 
0 
0 
1 
0 
0 
1 
0 
0 
1 
1 
1 
2 
2 
1 
0 
0 
0 
Placebo group 
2 
0 
1 
1 
0 
1 
0 
1 
1 
0 
1 
1 
0 
1 
1 
0 
0 
1 
0 
1 
1 
1 
2 
1 
* Data presented are number of patients reporteing each 
adverse effect. 
most adverse effects being mild in severity, 
appearing early during therapy, and manageable 
by adjustment in dose; however, there were 5 
dropouts due to adverse effects : two in the 
Aswagandha group (reasons : increased gastric 
acidity; withdrawal fatigue), and three in the 
placebo group (reasons: slowness and dullness; 
giddiness, weakness and fatigue; burning of 
eyes, burning while passing urine, and worsening 
of obsessive-compulsive symptoms). 
Most patients experienced the adverse 
effects early during the study (Table 7). At the 
study endpoint, the drugs were withdrawn 
abruptly. While no formal assessments of 
withdrawal were conducted, clinical records of 
these patients documented no withdrawal 
phenomena in either group. 
DISCUSSION 
India has a rich tradition in herbal 
medicine, and it is unfortunate that little work is 
being conducted by allopathic neuroscientists to 
identify elements in the herbal pharmacopoeia 
that might be of use in psychiatric disorders. The 
western pharmaceutical industry is already 
involved in the research of medicinal plants, and 
it would be doubly unfortunate if western 
scientists patent molecules of psychotropic 
value, that have been derived from Indian herbs. 
This subject has been discussed in greater detail 
elsewhere (Andrade et al.,1998). The present 
study was therefore a trail blazer in the field of 
anxiety disorders. 
Essentially, this study demonstrated a 
trend for the anxiolytic superiority of drug over 
placebo at week 2, and a statistically significant 
superiority at week 6. The advantage for 
Aswagandha was observed only with Hamilton 
Anxiety ratings, and with responder analyses, 
but not with global ratings; this may have bean 
because the latter had a narrower rating range, 
and were therefore less sensitive to clinical 
change. Aswagandha was well tolerated, with 
adverse effects being comparable to those 
observed with placebo. At 6 weeks, abrupt 
withdrawal did not appear to be associated with 
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anywithdrawal phenomena. Thus, Aswagandha 
appeared to have several of the advantages but 
none of the disadvantages of conventional 
anxiolytic drugs such as the benzodiazepines, 
the tricyclic antidepressants, and buspirone. This 
study therefore confirmed the preliminary 
observations of the unpublished open study of 
the experimental drug in patients with anxiety 
disorders (Manufacturer, data on file). 
Benzodiazepines produce anxiolysis 
within days; antidepressant drugs and buspirone 
reduce anxiety in approximately a fortnight. 
Speed of response was regrettably not addressed 
in this study. However, it is likely that significant 
response will be obtained in most patients within 
the first fortnight of therepy itself, as Aswagandha 
was near-significantJy superior to placebo at this 
time -point. Future studies need to address the 
magnitude of anxiolysis during the first week to 
ascertain the position of Aswagandha relative 
to conventional anxiolytic drugs. 
What might be the mechanism of action 
of Aswagandha? As reviewed earlier, 
Aswagandha has been shown to have GABA-
mimetic properties (Mehta et al.,1991; Kulkami 
et al.,1993); since GABA agonism has been 
linked to anxiolysis (Stah1,1998), it is conceivable 
that Aswagandha contains a constituent that 
alleviates anxiety by modulating GABA 
neurotransmission. 
The high placebo response rate (50%) was 
interesting; however, such high placebo response 
rates are well-known with anxiety disorders. 
Studies on patients with panic disorder, for 
example, have demonstrated placebo-response 
rates in the range of 40 to 50% (Schweizer et 
al.,1993; Londborg et al.,1998). 
This study had a few limitations. The 
sample size was relatively small, which might 
have been the reason why certain obvious 
statistical trends escaped significance. The 
inclusion of multiple diagnoses precluded an 
identification of the value of Aswagandha in 
each; samples for individual diagnoses were too 
small to permit subgroup analyses. 
It is concluded that further investigation 
of the anxiolytic properties of Withania somnifera 
are warranted, with particular reference to 
ethanolic extracts. Comparisons with convetional 
anxiolytic drugs are necessary. The relevance 
of the GABAergic properties of the extract to 
anxioiysis also require investigation. Long-term 
studies with structured withdrawal programmes 
should be conducted to document the long-term 
efficacy, safety, and dependence vs withdrawal 
profile of the treatment. Finally, attemts need to 
be made to identify the specific therapeutic 
element contained in the extract. 
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